Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subviral Agents01:29

Subviral Agents

713
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
713
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.2K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.2K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K
Retroviruses02:33

Retroviruses

15.6K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
15.6K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.2K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraintestinal administration of ulinastatin protects against sepsis by relieving intestinal damage.

The Journal of surgical research·2017
Same author

Spliceosome-associated factor CTNNBL1 promotes proliferation and invasion in ovarian cancer.

Experimental cell research·2017
Same author

A Ferroelectric Ceramic/Polymer Composite-Based Capacitive Electrode Array for In Vivo Recordings.

Advanced healthcare materials·2017
Same author

Does an Empty Nest Affect Elders' Health? Empirical Evidence from China.

International journal of environmental research and public health·2017
Same author

Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis.

Medicine·2017
Same author

Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.

Journal of medicinal chemistry·2017
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
Same journal

State-dependent neurotensin modulation in the brain: From network dynamics to pharmacological opportunity.

Current opinion in pharmacology·2026
See all related articles

Related Experiment Video

Updated: Mar 14, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

HCV NS5A replication complex inhibitors.

Min Gao1, Donald R O'Boyle1, Susan Roberts1

  • 1Bristol-Myers Squibb Company, Wallingford, CT 06492, USA.

Current Opinion in Pharmacology
|September 20, 2016
PubMed
Summary
This summary is machine-generated.

Direct antiviral agents (DAAs) offer a potential cure for chronic Hepatitis C virus (HCV) infection. Specifically, Hepatitis C virus NS5A inhibitors demonstrate remarkable potency and efficacy, leading to high cure rates with combination therapies.

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

12.1K
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

2.0K

Related Experiment Videos

Last Updated: Mar 14, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

12.1K
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

2.0K

Area of Science:

  • Virology and Pharmaceutical Sciences
  • Antiviral Drug Development

Background:

  • Hepatitis C virus (HCV) infection is a significant global health concern.
  • Direct antiviral agents (DAAs) represent a breakthrough in HCV treatment, offering potential eradication.
  • HCV NS5A replication complex inhibitors are a novel class of DAAs with high in vitro potency.

Purpose of the Study:

  • To highlight the success of direct antiviral agents (DAAs) in treating Hepatitis C virus (HCV).
  • To emphasize the role and efficacy of Hepatitis C virus NS5A inhibitors in combination therapies.
  • To underscore the significance of understanding the mechanism of action for potent NS5A inhibitors.

Main Methods:

  • Review of clinical trial data for direct antiviral agents (DAAs).
  • Analysis of in vitro potency data for Hepatitis C virus (HCV) NS5A inhibitors.
  • Examination of combination therapy outcomes in Hepatitis C virus (HCV) treatment.

Main Results:

  • Hepatitis C virus (HCV) NS5A inhibitors exhibit high potency (pM to low nM range).
  • Combination therapies including NS5A inhibitors achieve cure rates exceeding 90% in clinical trials.
  • Second-generation NS5A inhibitors are integral to current effective HCV treatment regimens.

Conclusions:

  • Direct antiviral agents (DAAs), particularly NS5A inhibitors, have revolutionized Hepatitis C virus (HCV) therapy.
  • The high efficacy of these agents necessitates further research into their precise mechanisms of inhibition.
  • Oral DAAs offer a historic opportunity to eradicate chronic Hepatitis C virus (HCV) infection.